All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer type (metastatic) cancer type (recurrent) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), immune chekpoint inhibitors vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 9LA, 2021 0.69 [0.55; 0.87]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
MYSTIC (DT ; PDL1>25%), 2020 0.85 [0.61; 1.18]
ORIENT-11, 2020 0.61 [0.40; 0.93]
0.76 [0.69 ; 0.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 19 65% 10,751 moderate critical deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.73 [0.64 ; 0.83 ] CheckMate 9LA, 2021, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 7 70% 4,536 moderate not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.70 [0.58 ; 0.85 ] CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 90% 5,418 moderate serious progression or deaths (PFS)detailed results CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 9LA, 2021 0.70 [0.57; 0.86]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.72; 1.53]
ORIENT-11, 2020 0.48 [0.36; 0.64]
0.73 [0.63 ; 0.85 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 17 87% 9,261 moderate low objective responses (ORR)detailed results CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 9LA, 2021 1.80 [1.31; 2.48]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
MYSTIC (DT ; PDL1>25%), 2020 0.87 [0.55; 1.37]
ORIENT-11, 2020 2.54 [1.63; 3.97]
1.48 [1.17 ; 1.87 ] CheckMate 026 (PDL1>5%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 16 83% 8,720 moderate low objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.62 [1.11 ; 2.38 ] IMpower-110 (TC3 or IC3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 6 85% 3,817 moderate not evaluable AE (any grade)detailed results EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
MYSTIC (DT ; PDL1>25%), 2020 0.43 [0.15; 1.24]
ORIENT-11, 2020 1.02 [0.03; 30.46]
0.49 [0.30 ; 0.82 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 9 66% 4,882 moderate serious AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
MYSTIC (DT ; PDL1>25%), 2020 0.86 [0.56; 1.35]
ORIENT-11, 2020 1.13 [0.74; 1.73]
0.73 [0.51 ; 1.04 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 9 89% 4,882 moderate not evaluable AE leading to death (grade 5)detailed results EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
MYSTIC (DT ; PDL1>25%), 2020 3.45 [1.24; 9.59]
ORIENT-11, 2020 0.31 [0.11; 0.90]
1.16 [0.78 ; 1.72 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 9 49% 4,882 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
MYSTIC (DT ; PDL1>25%), 2020 1.63 [0.91; 2.93]
ORIENT-11, 2020 0.70 [0.31; 1.55]
1.12 [0.74 ; 1.70 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020, ORIENT-11, 2020 9 81% 4,882 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.58 [1.08 ; 2.31 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 5 56% 3,006 low not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
MYSTIC (DT ; PDL1>25%), 2020 1.93 [1.22; 3.04]
1.31 [0.88 ; 1.93 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; PDL1>25%), 2020 3 60% 1,179 moderate not evaluable STRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 9LA, 2021 1.94 [1.36; 2.76]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
MYSTIC (DT ; PDL1>25%), 2020 1.05 [0.59; 1.87]
0.90 [0.60 ; 1.33 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 8 81% 4,164 moderate serious STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 9LA, 2021 1.95 [1.33; 2.84]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.04 [0.64 ; 1.67 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 80% 2,985 moderate serious TRAE (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 9LA, 2021 1.55 [0.94; 2.55]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
MYSTIC (DT ; PDL1>25%), 2020 0.17 [0.09; 0.30]
0.29 [0.19 ; 0.43 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 9 86% 5,415 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 9LA, 2021 1.44 [1.06; 1.94]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
MYSTIC (DT ; PDL1>25%), 2020 0.36 [0.22; 0.60]
0.37 [0.24 ; 0.59 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 9 92% 5,415 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 9LA, 2021 1.14 [0.38; 3.43]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
MYSTIC (DT ; PDL1>25%), 2020 0.94 [0.06; 15.13]
1.07 [0.68 ; 1.68 ] CheckMate 9LA, 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 9 0% 5,443 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 9LA, 2021 3.18 [1.94; 5.19]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
MYSTIC (DT ; PDL1>25%), 2020 1.04 [0.54; 2.03]
0.96 [0.62 ; 1.48 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, MYSTIC (DT ; all population), 2020, MYSTIC (DT ; PDL1>25%), 2020 8 79% 4,866 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 9LA, 2021 3.48 [2.00; 6.05]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
1.62 [1.01 ; 2.61 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 70% 4,236 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.88 [0.41; 149.53]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
2.68 [0.69 ; 10.35 ] CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 4,009 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.35 [0.06 ; 2.07 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 3,225 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 9LA, 2021 0.37 [0.22; 0.63]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.05 [0.01 ; 0.19 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 83% 4,236 moderate serious Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.97 [0.02 ; 48.81 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 9LA, 2021 0.36 [0.09; 1.37]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.23 [0.10 ; 0.50 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,932 moderate serious Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.98 [0.09 ; 10.85 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 9.87 [0.54; 181.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
4.22 [1.49 ; 12.00 ] CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 8 0% 5,559 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 9LA, 2021 0.97 [0.02; 49.27]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.73 [0.16 ; 3.34 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,236 moderate serious Decreased appetite TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 9LA, 2021 0.97 [0.24; 3.93]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.56 [0.29 ; 1.06 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,236 moderate serious Diabetes TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.40 [0.24 ; 8.12 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,355 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 9LA, 2021 7.06 [1.59; 31.30]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.17 [1.01 ; 4.65 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 8 22% 5,330 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.98 [0.06 ; 15.72 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 9LA, 2021 3.97 [0.84; 18.81]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
0.67 [0.31 ; 1.45 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 53% 4,236 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.38 [0.60; 3.15]
1.38 [0.60 ; 3.15 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
1.19 [0.36 ; 3.94 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
6.92 [2.21 ; 21.63 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,548 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.02 [0.27 ; 3.85 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 8 0% 5,249 moderate serious Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.88 [0.40 ; 8.89 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,606 moderate serious Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 9LA, 2021 1.95 [0.07; 58.39]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.77 [0.58 ; 5.34 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 10 0% 6,486 moderate critical Increase AST TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.88 [0.47 ; 7.56 ] EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 3 0% 2,345 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 9LA, 2021 2.46 [0.47; 12.75]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
2.11 [0.99 ; 4.50 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 5 0% 3,582 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.55 [2.24; 25.47]
7.55 [2.24 ; 25.47 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.39 [0.09 ; 1.76 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,711 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.05 [0.01 ; 0.38 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-042 (PDL1>1%), 2019 2 0% 1,781 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 9LA, 2021 4.93 [0.57; 42.41]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
3.26 [0.66 ; 16.22 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021 3 0% 1,934 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.94 [0.06 ; 57.80 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.70 [0.04 ; 11.17 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 2 0% 911 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 9LA, 2021 1.63 [0.39; 6.89]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.26 [0.08 ; 0.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 36% 4,236 moderate serious Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
1.93 [0.46 ; 8.10 ] EMPOWER lung1 (all population), 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 4,303 moderate serious Neutropenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 9LA, 2021 0.71 [0.41; 1.24]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.04 [0.01 ; 0.29 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 86% 4,236 moderate serious Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.65 [0.23 ; 11.94 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.44 [0.06 ; 3.02 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,478 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
0.98 [0.02 ; 49.83 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.08 [0.00 ; 1.43 ] KEYNOTE-042 (PDL1>1%), 2019 1 0% 1,251 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
ORIENT-11, 2020 0.98 [0.09; 10.96]
3.06 [1.34 ; 6.99 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 8 18% 5,249 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 9LA, 2021 5.89 [0.29; 118.02]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.57 [0.38 ; 6.49 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 6 0% 4,329 moderate serious Pyrexia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.66 [0.05 ; 8.61 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016 2 0% 834 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 9LA, 2021 11.88 [0.66; 213.53]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.69 [0.70 ; 4.09 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020, ORIENT-11, 2020 8 3% 5,575 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
1.97 [0.07 ; 59.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
12.07 [0.67 ; 217.19 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
3.88 [0.61 ; 24.61 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 62% 2,162 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
5.00 [0.58 ; 43.09 ] CheckMate 026 (PDL1>1%), 2016 1 0% 530 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.44 [0.06 ; 3.17 ] CheckMate 026 (PDL1>1%), 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 3 0% 2,085 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
CheckMate 9LA, 2021 1.09 [0.44; 2.70]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.09 [0.02 ; 0.48 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 75% 4,236 moderate serious Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.78 [0.08 ; 7.49 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 3 0% 2,162 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78]
CheckMate 9LA, 2021 1.17 [0.35; 3.88]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71]
KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36]
MYSTIC (D ; all population), 2020 0.07 [0.00; 1.18]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.32 [0.10 ; 1.07 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 9LA, 2021, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 32% 4,236 moderate serious hepatitis (Autoimmune) AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
KEYNOTE-407, 2018 10.24 [0.56; 188.30]
5.05 [0.55 ; 46.09 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Acute kidney injury AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
0.24 [0.01 ; 5.34 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Alopecia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
KEYNOTE-407, 2018 0.33 [0.03; 3.22]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.42 [0.09 ; 1.95 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 4 0% 2,699 moderate not evaluable Anaemia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.03 [0.01; 0.13]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
KEYNOTE-189, 2018 1.07 [0.67; 1.71]
KEYNOTE-407, 2018 0.72 [0.46; 1.11]
MYSTIC (D ; all population), 2020 0.16 [0.07; 0.34]
MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.20 [0.08 ; 0.55 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 92% 3,855 moderate serious Arthralgia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
KEYNOTE-407, 2018 2.03 [0.37; 11.17]
1.52 [0.33 ; 6.97 ] EMPOWER lung1 (all population), 2021, KEYNOTE-407, 2018 2 0% 1,255 low not evaluable Asthenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
KEYNOTE-189, 2018 1.83 [0.78; 4.31]
KEYNOTE-407, 2018 0.60 [0.21; 1.66]
MYSTIC (D ; all population), 2020 0.95 [0.41; 2.23]
MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.93 [0.61 ; 1.43 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Back pain AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
MYSTIC (D ; all population), 2020 0.32 [0.03; 3.05]
MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.48 [0.13 ; 1.77 ] EMPOWER lung1 (all population), 2021, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 3 0% 2,141 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
0.48 [0.02 ; 14.38 ] EMPOWER lung1 (all population), 2021 1 0% 697 NA not evaluable Colitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.04 [0.50; 8.23]
2.04 [0.50 ; 8.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Constipation AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
KEYNOTE-189, 2018 2.00 [0.22; 18.06]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 0.95 [0.06; 15.31]
MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.21 [0.48 ; 3.01 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
KEYNOTE-407, 2018 0.67 [0.11; 4.04]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.90 [0.25 ; 3.23 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 5 0% 3,158 low not evaluable Decreased appetite AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.06; 15.46]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 3.02 [0.36; 25.28]
KEYNOTE-407, 2018 1.21 [0.37; 4.02]
MYSTIC (D ; all population), 2020 1.44 [0.40; 5.14]
MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.49 [0.78 ; 2.85 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.16 [0.02; 1.32]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
KEYNOTE-189, 2018 1.79 [0.71; 4.50]
KEYNOTE-407, 2018 1.88 [0.69; 5.16]
MYSTIC (D ; all population), 2020 0.38 [0.07; 1.96]
MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
1.08 [0.51 ; 2.29 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 44% 3,855 moderate serious Dyspnoea AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 1.93 [0.17; 21.41]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
KEYNOTE-189, 2018 0.67 [0.30; 1.48]
KEYNOTE-407, 2018 3.04 [0.31; 29.44]
MYSTIC (D ; all population), 2020 1.61 [0.58; 4.47]
MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.10 [0.66 ; 1.84 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 0% 3,855 moderate serious Epistaxis AE (grade 3-4)detailed results KEYNOTE-407, 2018 1.01 [0.02; 50.94]
1.01 [0.02 ; 50.94 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Fatigue AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.72 [0.16; 3.24]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
KEYNOTE-189, 2018 2.37 [0.89; 6.34]
KEYNOTE-407, 2018 0.82 [0.33; 2.01]
MYSTIC (D ; all population), 2020 1.20 [0.47; 3.07]
MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.10 [0.69 ; 1.75 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (DT ; all population), 2020 6 13% 3,855 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.06 [0.00; 1.03]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86]
0.05 [0.01 ; 0.41 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Hypertension AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.24 [0.01; 5.34]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68]
0.48 [0.10 ; 2.29 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable Hyperthyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypophysitis AE (grade 3-4)detailed results KEYNOTE-407, 2018 4.05 [0.18; 90.23]
4.05 [0.18 ; 90.23 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-407, 2018 2.02 [0.07; 60.40]
2.02 [0.07 ; 60.40 ] KEYNOTE-407, 2018 1 0% 558 NA not evaluable Increase AST AE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74]
EMPOWER lung1 (all population), 2021 4.87 [0.57; 41.91]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
5.45 [1.59 ; 18.72 ] CheckMate 026 (PDL1>1%), 2016, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3 0% 1,776 moderate not evaluable Increased ALT AE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 5.82 [0.29; 116.64]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
5.03 [0.87 ; 28.91 ] EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020 2 0% 1,246 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 15:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743